Stanford University

Division of Endocrinology and Diabetes

Division of Endocrinology and Diabetes
300 Pasteur Drive
Stanford, CA 94305
United States
Call 650-723-5395 Email this location
Stanford University is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Darrell Wilson, MD, the TrialNet team at Stanford University is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.   

Our Team

Principal Investigators 
Starting with his initial training as an electrical engineer, Dr. Darrell Wilson has applied technology to improve the care of children and adolescents with endocrine problems, particularly emphasizing technology in carbohydrate abnormalities. A Professor of Pediatrics at Stanford University, he is an internationally known clinical researcher concentrating in the area of pediatric diabetes and has published over 300 peer reviewed articles and chapters. He has been the Principal Investigator at Stanford University for TrialNet since its inception. He is a co-investigator on the NIH funded, multi-center Diabetes Research in Children Network (DirecNet). Over the past decade, this group has been devoted to testing how new technology such as glucose sensors can help children with diabetes, and has been extraordinarily productive. Further, he is a co-investigator on a number of Juvenile Diabetes Research Foundation funded clinical investigations devoted to the development of artificial pancreas. Dr Wilson is a key member of Stanford University’s clinical research infrastructure, serving as the Chair of one of Stanford’s IRB panels as well as a member on the NIH funded CTRU advisory committee. At Stanford, he helps coordinates the clinical care for about 800 children and adolescents with diabetes. As an educator, he teachs medical students, residents, fellows, and clinical researchers across the Stanford campus and serve as an Associate Program Director for the Stanford University Pediatric Endocrine Fellowship training program.
Research Coordinators 
Stanford University TrialNet coordinator Trudy Esrey’s youngest daughter Kerry was diagnosed with type 1 diabetes at the age of 11.“Like most families, it is a day we will never forget,” Trudy says. “Since Kerry’s first weeks of diagnosis, we wanted to be part of the solution to find a cure, prevent the disease in family members at risk, and work to maintain or restore insulin production in those already diagnosed . It is empowering to work toward these goals, not just for us as researchers, but also for the lovely families that step up to participate in the studies. Boots on the ground; let’s get it done.” As an RD, CDE, Trudy works at Stanford’s pediatric diabetes clinic in addition to working as TrialNet coordinator. She has worked tirelessly as a volunteer with her local JDRF chapter, including ten years (and counting) as Volunteer Coordinator for the JDRF Silicon Valley One Walk. Kerry has been there right by her side, also advocating and volunteering in research studies and working with TrialNet. “I’m so pleased to say that Kerry has not let T1D stop her from doing anything in her life, including running an occasional marathon. And to have her help us with TrialNet recruitment has been a joy. Her empathy is priceless and her presence endearing. Families really relate to her.” Trudy encourages all families affected by T1D to get involved in some way, and says that TrialNet is one of the best ways to do so.
Bonnie has been with the Department of Pediatric Endocrinology at Stanford University for over 30 years. She has worked on the TrialNet studies since the beginning. “I have seen many wonderful and exciting changes in the treatment and management of Type 1 Diabetes over the years. Every new discovery is one step closer to prevention and a cure. This is why I know my work with TrialNet is so important. I can see that I am changing people’s lives for the better!.”
Karen is a Research Coordinator at the Stanford University Clinical Center. She joined the team back in 2013 initially working mainly on recruitment and later moving onto coordinating prevention trials. She came from previously working in the high tech industry, “I missed the direct human interaction too much and when I found our TrialNet team at Stanford – I knew I was home!” “I enjoy so much meeting new families and being able to provide information for them about our screening services and prevention trials. I truly believe in the core fundamentals of TrialNet. If I can help families find out if they are at risk of developing diabetes before symptoms show up then I have done my job.” “My favorite part of working with TrialNet is meeting so many wonderful families. I am always very excited to see them and hear what has been happening in their lives. I am often pleasantly surprised receiving messages with updates about their lives such as graduations, birthdays and other news. They know our team cares for them as a family beyond screening and clinic services.” Karen is actively involved in the community, she loves volunteering at the Elementary school as a co-chair of the anti-bullying project Cornerstone. As well as directly in the Stanford community as one of the leads in the 2016 Lean In cohort. Karen lives in San Jose, California with her two children and her rescued dog Bella.
Arrizon Ruiz
Nora has worked with Pediatric Endocrinology for 3 years in the outpatient clinic and has recently joined the TrialNet team as an Assistant Clinical Research Coordinator. She is a Bay area native and a bilingual English/Spanish speaker. She is happily married to her husband Sal of 20 years and are raising four kids in the city of Redwood City. Nora enjoys art, watching movies, and supporting and rooting on her kid’s sports activities and school endeavors. She is currently attending the night Working Adult program in Cañada College to complete her Bachelor’s degree in Psychology. Nora is “very happy to continue her career in the department of Endocrinology and excited to offer excellent service to our families and contribute to the prevention and cure of type 1 diabetes!”

Regional Affiliates

Affiliates provide opportunities for people who do not live near Stanford University. The affiliate sites listed below work with Stanford University to offer convenient participation in our research programs

Desert Senita Community Health Center
410 N. Macate St, Ajo, AZ 85321


Claudia Vogel, MD
10561 Jeffrey Street, Henderson, NV 89052

Las Vegas

Horizon View Medical Center - Pediatric Endocrinology
6850 N Durango D, Las Vegas, NV 89149


Valley Childrens Hospital
9300 Valley Children's Place, Madera, CA 93636


Banner Health Cardon Childrens Medical Center
1400 S. Dobson Rd, Mesa, AZ 85202


Childrens Hospital of Orange County
1201 West La Veta, Orange, CA 92868


Noesis Pharma
16601 N 40th St, Phoenix, AZ 85032


Pediatric Endocrinology and Diabetes Clinic
7010 East Chauncey Lane, Phoenix, AZ 85054


Pediatric Endocrinology of Phoenix
15600 N Black Canyon Hwy, Phoenix, AZ 85053

San Diego

University of California-San Diego
3020 Childrens Way MC 5105, San Diego, CA 92123

Santa Barbara

Sansum Diabetes Research Institute
2219 Bath Street, Santa Barbara, CA 93105

Santa Clara

Kaiser Permanente Santa Clara
710 Lawrence Expwy, Pediatrics Endocrinology, Santa Clara, CA 95051


Beaver Medical Group Yucaipa Valley
33758 Yucaipa Blvd, Yucaipa, CA 92399

Research Studies

Risk Screening

Pathway to Prevention

If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to stop it. The first step is to sign up for Pathway to Prevention screening to determine your risk of developing T1D.


Prevention Study

Abatacept - Closed to Enrollment - Study Ongoing

TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 to stage 2) and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression.


Teplizumab (Anti-CD3)

We tested the drug teplizumab to see if it could delay or prevent progression of early stage T1D (stage 2) and prevent clinical diagnosis (stage 3). In earlier studies in people newly diagnosed (stage 3), teplizumab helped to prolong insulin production.


Hydroxychloroquine (HCQ)

We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D.



Long-Term Investigative Follow-Up in TrialNet (LIFT)

Once your study ends, we're still here for you. Participant monitoring and continued involvement helps us learn more about T1D.